We're on a Mission to Find The Cure For Cancer By Delivering Oncolytic Viruses That Are Designed To Attack Cancer
Employees: 11-50
Total raised: $25M
Founded date: 2014
Funding Rounds 1
| Date | Series | Amount | Investors |
| 26.06.2023 | Series B | $25M | - |
Mentions in press and media 12
| Date | Title | Description |
| 14.11.2024 | Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock | SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced tha... |
| 29.07.2024 | Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor | SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, announced a $2 million stra... |
| 26.06.2023 | Calidi Biotherapeutics Raises $25M in Series B Funding | Calidi Biotherapeutics, a San Diego, CA-based clinical-stage biotechnology company, raised $25M in Series B funding. The round was led by Jackson Investment Group, who has funded an initial investment of $5M, and participation from Calidi C... |
| 26.06.2023 | San Diego-based Calidi Biotherapeutics raises USD 25 million in Series B funding | SAN DIEGO – Jackson Investment Group (“JIG”), which has contributed an initial investment of USD 5 million, and Calidi Cure, LLC, a group of new and existing investors led by Allan Camaisa, CEO and Chairman of Calidi, have both committed US... |
| 26.06.2023 | Calidi Biotherapeutics raises $25M in Series B Funding to continue advancing their pipeline | - |
| 23.06.2023 | Calidi Biotherapeutics Inks $25M in Series B | SAN DIEGO, CA, Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company, announced a $25M in Series B funding led by Jackson Investment Group. >> Click here for more funding data on Calidi Biotherapeutics >> To e... |
| 23.06.2023 | Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer | Financing led by Jackson Investment Group (JIG) with participation from Calidi Cure, LLC, a consortium of new and existing investors led by Allan Camaisa, CEO and Chairman of Calidi Biotherapeutics, and supported by the First Light Acquisit... |
| 23.06.2023 | Calidi Biotherapeutics Announces Commitment of $25 Million in Series B Funding to Advance Stem Cell-Based Platforms for the Delivery and Potentiation of Oncolytic Viruses to Treat Cancer | - |
| 07.03.2022 | Calidi Eyes Public Markets in SPAC Merger with Edoc | Rendering courtesy of Calidi Therapeutics Calidi uses stem cells to protect oncolytic viruses from the body’s immune system. Calidi Biotherapeutics is planning to become a publicly traded company sometime in the second quarter of this year.... |
| 23.01.2020 | Calidi Biotherapeutics Secures Series A Funding | Calidi Biotherapeutics, Inc., a San Diego, CA-based clinical‐stage immuno-oncology company at the forefront of cell-based oncolytic virus immunotherapies for cancer, raised a Series A funding round of undisclosed amount. Backers included Ko... |
Show more